Centralized price bidding

Drug developer Shanghai Junshi Biosciences said on Sunday its board has approved a plan to buy back some of its A-shares.

FAST NEWS: Junshi Biosciences announces A-Share buyback

The latest: Drug developer Shanghai Junshi Biosciences Co. Ltd. (1877.HK; 688180.SH) said on Sunday its board has approved a plan to buy back some of its A-shares for up to 58 yuan per…
1877.HK 688180.SHG

Recent Articles

RELATED ARTICLES

  1. The biotech company has been dogged by multiple challenges recently, including declining revenue, ongoing losses and a recent rejection by one of its overseas partners.
    Junshi hopes new scientist CEO can cure its woes
    1877.HK 688180.SHG
  2. Junshi narrows its losses but delivers no cure for share price woes
    1877.HK 688180.SHG
  3. Akeso marks profit milestone with swift rights issue
    9926.HK
  4. Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
    1952.HK
  5. Facing revenue crisis, Ascletis Pharma tries to bulk up with obesity drugs
    1672.HK
  6. BeiGene’s aggressive expansion brings revenue jolt
    BGNE.US 6160.HK 688235.SHG
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva